Ikarian Capital’s Repare Therapeutics RPTX Stock Holding History

Ikarian Capital’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-190,410	Closed	-$5.86M	–	253
2020 Q3	$5.86M	Buy	+190,410	New	+$5.04M	0.42%	62

Other funds holding RPTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ikarian Capital's RPTX Position: Q4 2020 in Review

Ikarian Capital sold out of Repare Therapeutics (RPTX) in Q4 2020, closing a stake of 190,410 shares — an estimated $5.86M sold.

Ikarian Capital first reported a position in RPTX in Q3 2020 and held it in 1 quarter. The position peaked at $5.86M in Q3 2020. 63 funds tracked by Wall St. Rank hold RPTX as of Q4 2020.

Ikarian Capital reported no remaining Repare Therapeutics position as of Q4 2020 after selling out during the quarter.
Ikarian Capital sold 190,410 Repare Therapeutics shares in Q4 2020, an estimated $5.86M.
Ikarian Capital first reported a position in Repare Therapeutics in Q3 2020 and held it in 1 quarter.
Ikarian Capital's Repare Therapeutics position peaked at $5.86M in Q3 2020.
63 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.